Reuters logo
BRIEF-Bristol-Myers Squibb says phase 3 study evaluating the safety and efficacy of adjuvant Opdivo in resected high-risk melanoma patients meets main goal
July 5, 2017 / 10:36 AM / in 5 months

BRIEF-Bristol-Myers Squibb says phase 3 study evaluating the safety and efficacy of adjuvant Opdivo in resected high-risk melanoma patients meets main goal

July 5 (Reuters) - Bristol-myers Squibb Co

* Phase 3 study evaluating the safety and efficacy of adjuvant Opdivo in resected high-risk melanoma patients meets primary endpoint

* Bristol-Myers Squibb - ‍Opdivo demonstrates superior recurrence-free survival versus Yervoy (ipilimumab) in adjuvant setting in CheckMate -238​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below